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A B S T R A C T
Dietary plant sterols and stanols as present in our diet and in functional foods are well-known for their inhibitory
effects on intestinal cholesterol absorption, which translates into lower low-density lipoprotein cholesterol
concentrations. However, emerging evidence suggests that plant sterols and stanols have numerous additional
health effects, which are largely unnoticed in the current scientific literature. Therefore, in this review we pose
the intriguing question “What would have occurred if plant sterols and stanols had been discovered and em-
braced by disciplines such as immunology, hepatology, pulmonology or gastroenterology before being posi-
tioned as cholesterol-lowering molecules?” What would then have been the main benefits and fields of appli-
cation of plant sterols and stanols today? We here discuss potential effects ranging from its presence and function
intrauterine and in breast milk towards a potential role in the development of non-alcoholic steatohepatitis
(NASH), cardiovascular disease (CVD), inflammatory bowel diseases (IBD) and allergic asthma. Interestingly,
effects clearly depend on the route of entrance as observed in intestinal-failure associated liver disease (IFALD)
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during parenteral nutrition regimens. It is only until recently that effects beyond lowering of cholesterol con-
centrations are being explored systematically. Thus, there is a clear need to understand the full health effects of
plant sterols and stanols.
1. Introduction
Nowadays, most humans are typical omnivores. However, from
fossil characteristics, extensive evidence clearly indicates that a plant-
based diet was the traditional eating pattern of our distant ancestors
[1]. In those days, meat was only used when available, but the majority
of calories and concomitant nutrients were plant-derived. Moreover,
cholesterol levels in the diet were typically very low, while at the same
time many foods enhanced cholesterol elimination through the intes-
tine. Still, also in those days, cholesterol was an essential component for
human life and the body developed mechanisms such as endogenous
cholesterol synthesis and reuptake of bile acids in the lower parts of the
small intestine in order to preserve cholesterol homeostasis. In this
balanced condition, serum cholesterol concentrations remained low,
whereas nowadays a higher cholesterol intake adds to the fact that high
intakes of plant based foods which should maintain low intestinal
cholesterol absorption are no longer present [1]. Typical nutrients of
these original ancient plant-based diets are soluble fibers, poly- and
monounsaturated fatty acids (PUFA and MUFA), vegetable proteins, fat-
and water-soluble vitamins and minerals, and other phytonutrients in-
cluding plant sterols and stanols, a dietary composition that is now
generally considered as being healthy. Indeed, many dietary guidelines
stress the advantages of plant-based diets providing large amounts of
fruits, vegetables, soy, nuts and pulses [2–5]. In addition, it can be
envisaged that intakes of plant sterols, which are structural components
of plants, analogue to cholesterol in animals, in these ancient diets were
2.5 to 5 times higher as compared to levels in our current diets [1]. An
intriguing question therefore is whether these plant sterols are desired
or unwanted by the human body, since plant sterol concentrations are
tightly regulated by absorption and secretion via intestinal and hepatic
ATP-binding cassette subfamily G member 5/8 (ABCG5/G8) transporter
activity. Plant sterols were immediately considered to be harmful after
the identification of two sisters suffering from phytosterolemia, also
known as sitosterolemia, back in 1974 by Bhattacharyya and Connor
[6]. Phytosterolemia is a rare autosomal recessively inheritable sterol
storage disease characterized by mutations in either one of the ABCG5/
G8 heterodimer parts, which translates into intestinal hyper absorption
and decreased biliary secretion of plant sterols [7–11]. It is estimated
that worldwide about 100 cases of homozygous sitosterolemia exist,
which have clearly distinct pathological phenotypes [12]. The first si-
tosterolemic patients as described by Bhattacharyya and Connor [6]
were characterized by tendon and tuberous xanthomas, while no other
physical, mental, or biochemical abnormalities were detected. The link
between sitosterolemia and atherosclerosis was shown for the first time
by Shulman et al. [13]. They therefore postulated that plant sterols
were highly atherogenic. Interestingly, more recently, sitosterolemic
patients have been diagnosed without any signs of premature cardio-
vascular disease (CVD), despite having highly elevated serum plant
sterol concentrations [14]. This observation challenged the original
concept of plant sterols being the only culprit of high CVD risk in
phytosterolemia. The question is what can be learned from these ap-
parently “non-symptomatic” phytosterolemic subjects in terms of resi-
lience against elevated serum plant sterol concentrations. Alternatively,
it might not be resilience as such, but the lack or presence of another
characteristic that needs to be present before elevated plant sterol
concentrations translate into cardiovascular complaints. Finally, it
might also be that elevated plant sterol concentrations are not involved
in the pathophysiology of CVD at all, but are only a so-called flag or
surrogate marker for a yet unknown risk factor in sitosterolemic pa-
tients. Notably, individuals with heterozygous sitosterolemia, which is
far more prevalent, have either normal or only modestly elevated serum
plant sterol concentrations, indicating that regulation of one functional
allele of the ABCG5 or ABCG8 monomer is almost sufficient to maintain
normal intestinal absorption and/or biliary secretion plant sterols.
More importantly, individuals with heterozygous phytosterolemia did
not show any clinical abnormalities or premature atherosclerosis [11].
Several years before the discovery of the defect in the ABCG5/G8
genes in sitosterolemic patients, Peterson and colleagues [15,16] as
well as the research group of Pollak [17] were exploring the applic-
ability of sitosterol-rich soy bean plant sterols as a tool to lower in-
testinal cholesterol absorption with the ultimate aim to lower circu-
lating serum cholesterol concentrations. This was also the era in which
Ancel Keys, in the famous Seven Countries Study, suggested that in-
creased serum total cholesterol concentrations resulting from high sa-
turated fat (SAFA) intake were the culprit of atherosclerosis and cor-
onary heart diseases [18–20]. The advice was to eat more healthy diets
rich in MUFA and PUFA, and low in SAFA as typically consumed on
Crete in those days to maintain healthy serum cholesterol concentra-
tions. Later studies showed that in particular cholesterol carried in LDL
particles related to coronary heart disease (CHD) risk and occurring
events. These observations caused an enormous interest in identifying
effective pharmacological as well as dietary lifestyle interventions to
lower serum LDL-cholesterol concentrations. In this context, the success
of pharmacological approaches such as the different types of statins,
inhibitors of the rate limiting enzyme 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase (HMG-CoA reductase), following the identifica-
tion of the LDL-receptor (LDLr) regulatory pathways by Goldstein and
Brown [21], can be explained. Next, drugs like ezetimibe that lower
intestinal cholesterol uptake by blocking the Niemann-Pick C1 Like 1
(NPC1L1) receptor were introduced to further lower serum LDL-cho-
lesterol through combination therapies [22,23]. More recently, PCSK9
inhibitors have been developed that even further enhance LDLr-medi-
ated clearance of LDL particles from the circulation in hypercholester-
olemic patients [24].
After the initial studies by Peterson and Pollak and the apparent
absence of any toxicity of plant sterols, these components became of
interest for cholesterol-lowering therapies [25]. Commercial products
based on sitosterol preparations such as Cytellin® and Sito-Lande® have
been used as pharmacological treatments of hypercholesterolemia and
have been marketed until the 1980s and 1990s respectively. Their ef-
ficacy was however rather low and doses of 3 to up to 30 g per day were
needed to lower cholesterol [26]. The pharmacological use of plant
sterols further remained limited to cases of hyperlipidemia, mainly due
to the high costs associated to produce pharmaceutical grade sitosterol.
With the introduction of statins as potent cholesterol-lowering
medication, interest in plant sterols decreased and there was a rela-
tively “silent” plant sterol period, also due to the sub-optimal physi-
cochemical characteristics of the available preparations hampering
practical applicability to enrich for instance common foods with plant
sterols. The use of plant sterol- or stanol-enriched diets celebrated its
renaissance in the early 1990s when food industries focused on the
development of functional foods based on new insights showing that
physical properties and handling of plant sterols and stanols could be
improved by esterification with fatty acids [27]. Initially, plant stanols
(the saturated counterpart of plant sterols) were esterified with dietary
fatty acids, which increased their fat-solubility and therefore their ap-
plicability to be incorporated into fat-rich foods, like margarines [28].
A few years later also margarines and spreads with added plant sterol
esters, and mixtures of sterol and stanol esters became available as
functional foods. The cholesterol-lowering efficacy of foods with added
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plant sterols or stanols or their mixtures in esterified as well as in their
free forms has been demonstrated in>120 randomized, placebo con-
trolled intervention studies [29]. In a recent consensus panel paper of
the European Atherosclerosis Society (EAS), it was concluded that a
daily intake of 2–3 g plant sterols or stanols lowers serum LDL-choles-
terol concentrations up to 12% [30]. Regarding the mechanism un-
derlying the LDL-cholesterol lowering effects, there is no clear con-
sensus. The common idea is that plant sterols decrease cholesterol
incorporation into mixed micelles thereby lowering cholesterol bioa-
vailability and absorption [31]. However, recently more challenging
mechanisms such as plant sterol induced elevation in trans intestinal
cholesterol excretion (TICE), i.e. stimulated efflux of cholesterol from
the brush border membrane into the intestinal lumen, have been pro-
posed [32]. Irrespective of the underlying mechanism, advising plant
sterols or stanols as part of a healthy diet to lower serum LDL-choles-
terol concentrations is nowadays mentioned in international guidelines
for the management of hyper- or dyslipidemia [33,34]. In terms of
societal impact, two recent reports assessing the cost-effectiveness of
foods with added plant sterols or stanols as a primary prevention
strategy for people with CVD in the UK [35] and the potential health-
care cost savings that could be derived from plant sterol/stanol intake
in the European Union [36] have shown their potential benefits on
public health including health economics. The report written by the
non-profit organization Frost & Sullivan on request of Food Supple-
ments Europe (http://www.foodsupplementseurope.org/value-of-
supplementation) indicated that the total avoidable healthcare cost
savings from plant sterol/stanol supplements in Europe is €5.3 billion
per year. After subtracting implementation costs of €1.2 billion, the
annual saving in Europe is €4.1 billion. In other words, the return from
healthcare savings for each €1 spent on supplementation is €4.37.
Moreover, Yang et al. [35] have described that daily intake of spreads
with added plant sterols or stanols could reduce CVD risk, especially in
men and older age groups. Assuming a 50% compliance rate, over a
period of 20 years, 69 CVD events per 10,000 men and 40 CVD events
per 10,000 women aged 45–85 years could be saved. The intriguing
thought is that - if the additional potential benefits of consuming plant
sterols or stanols, as described in this review are consistent- health care
costs savings may increase even further.
2. Plant sterol physiology
Our current Western-type habitual diets provide on average 300mg
plant sterols and 17–24mg plant stanols per day with somewhat higher
intakes (up to 600mg sterols) in vegetarians [37]. Plant sterols and
stanols are present mainly as fatty acid esters, hydroxycinnamic acid
esters, and glycosides [38]. Within the gastro-intestinal tract, all ester
bonds are cleaved by specific enzymes, resulting in the formation of free
plant sterols and stanols. The predominant plant sterols and stanols in
our habitual diets are sitosterol (66%), campesterol (22%), stigmasterol
(8%), and sitostanol plus campestanol (4%) which are present in bread,
cereals, vegetables, fruits and (vegetable) oils and products based on
these oils [37]. The free plant sterols and stanols are subsequently in-
corporated into mixed micelles, a process in which they interfere with
cholesterol incorporation into these micelles. This effect at least partly
contributes to their lowering effect on intestinal cholesterol absorption.
Like cholesterol, plant sterols are taken up from the mixed micelles into
enterocytes via the NPC1L1 receptor, located at the apical membrane
[39]. NPC1L1 is the pharmacological target for ezetimibe, which effi-
ciently lowers both intestinal absorption of cholesterol as well as of
plant sterols and stanols [40]. After uptake into the enterocytes, me-
tabolism of plant sterols is different from that of cholesterol. The plant
sterols and stanols are poor substrates for intestinal acyl-CoA choles-
terol acyltransferase (ACAT), which explains why plant sterols are not
easily esterified and remain in the free form within the cell. As a con-
sequence, the free plant sterols, in contrast to cholesterol esters, are not
efficiently incorporated into chylomicrons. Instead, the majority of the
free intracellular plant sterols and stanols are excreted back into the
intestinal lumen via the ATP-driven transporter heterodimer ABCG5/
G8. This explains why net intestinal absorption of plant sterols is very
low, varying from 0.5% for sitosterol to 1.9% for campesterol [41],
which is considerably lower compared to cholesterol absorption rates
which varies between subjects from 19 and 77% [42]. The small
amounts of plant sterols and stanols that enter the circulation are ra-
pidly taken up by the liver and secreted into bile via hepatic ABCG5/
G8, further explaining the very low plasma plant sterol and stanol
concentrations. Plant sterols are found in all lipoproteins with the
highest concentrations in LDL and high-density lipoproteins (HDL)
Fig. 1. Plant sterol and stanol physiology in the classical paradigm.
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[30]. In contrast to cholesterol, plant sterols are not synthesized en-
dogenously so each plant sterol molecule found in the circulation is
derived from the diet. Together with the observation that plant sterols
are not further metabolized into for example bile acids, but excreted in
bile as such, makes the classical paradigm of plant sterol physiology
rather straightforward (Fig. 1). Moreover, in the early days of plant
sterol and stanol research, these compounds were considered as mole-
cules that entered the intestinal lumen with only minimal spill over into
the circulation. Nowadays, it becomes increasingly appreciated that
plant sterols and stanols do enter the circulation. Moreover, although
circulating concentrations are very low as compared to cholesterol, they
are taken up by different tissues [30] and may affect various (patho)
physiological processes (Fig. 2).
Until recently, plant sterols and stanols were seen as inert molecules
that enter the gastro-intestinal tract either via diet or via biliary se-
cretion, lower cholesterol absorption via disturbing luminal mixed
micelle composition, are hardly absorbed and leave the body un-
modified via the feces. The small amounts of plant sterols and stanols
that are absorbed are rapidly taken up by the liver and excreted via bile
into the gastro-intestinal tract. According to the classical paradigm,
plant sterols and stanols hardly appear in the circulation, while
knowledge on the effects – beyond LDL-cholesterol lowering - of ab-
sorbed plant sterols and stanols on metabolic and functional markers
related to health or disease is scarce.
In the new paradigm, plant sterols and stanols enter the gastro-in-
testinal tract either via diet or via biliary secretion, lower cholesterol
absorption via different mechanisms including a decrease in micellar
incorporation of cholesterol. Plant sterol and stanol absorption is low,
but plasma concentrations increase after higher intakes. The small
amounts of plant sterols and stanols that are absorbed are rapidly taken
up by the liver and transported by lipoproteins to other tissues where
they can have (patho)physiological effects beyond lowering intestinal
cholesterol absorption. 1: Plant sterols interfere with mixed micelle
composition in the intestinal lumen thereby lowering cholesterol
bioavailability and fractional cholesterol absorption. 2: In contrast to
cholesterol, which absorption varies between subjects from 19 and
77%, absorption of plant sterols and stanols is much lower varying
between 0.5 and 1.9%. Thus, chylomicrons contain more cholesterol
than plant sterols although dietary intakes are comparable, around
300mg/day. 3: During transport from the intestinal lumen into the
circulation, plant sterols and stanols can easily interfere with all types
of immune cells as present in the Peyer's patches. 4: Plant sterols and
stanols are taken up by immune cells in the circulation and are also
incorporated into red blood cells and platelets. Hepatic plant sterol
levels can easily increase (5) and interact with different cell types such
as the Kupffer cells. 6: Plant sterols are also incorporated into other
peripheral tissues including the vascular wall, the lungs, the brain and
into breast milk. 7: While on a parenteral nutrition (PN) feeding pro-
tocol, plant sterol concentrations can be greatly increased, since these
formulae like, for example, Intralipid are based on soy bean oil which is
rich in plant sterols. Infusing these formulae directly into the circulation
circumvents the selective intestinal wall.
3. Plant sterols in breast milk
Cholesterol is an important building block for cell synthesis in
newborns, a precursor for several hormones, bile acids and vitamin D,
explaining why breast milk is relatively rich in cholesterol. Still, cho-
lesterol represents< 0.5% of the milk lipid fraction, which mainly
contains triacylglycerols [43]. Especially during early postnatal life,
newborns need large amounts of cholesterol to meet their requirements.
Moreover, infants with low serum cholesterol concentrations may be
more susceptible for allergic diseases and infections [44]. The im-
portance of dietary cholesterol for infants is further illustrated by the
finding that breast milk remains rich in cholesterol, even when a lac-
tating mother is treated with cholesterol-lowering plant stanol therapy
[45] Therefore, in breast milk, cholesterol should be considered bene-
ficial instead of potentially harmful. The cholesterol in breast milk
originates from uptake from the circulation as well as local synthesis.
LDL is the predominant cholesterol donating lipoprotein to the baso-
lateral membrane of the secretory cells in the mammary tissues, where
LDLr indeed have been identified [46]. This cholesterol is incorporated
into the milk at the apical side of the secretory cells, predominantly via
extrusion of fat globules from the endoplasmatic reticulum of the
mammary cells [47]. However, also ABCA1 and ABCG1 transporter
mediated secretion to the cholesterol acceptor apoA-I has been
Fig. 2. Plant sterol and stanol physiology after the paradigm shift.
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suggested [48].
Besides cholesterol, breast milk also contains plant sterols, although
in much lower quantities [49]. Cholesterol is generally present in the
millimolar range, whereas plant sterols are present in micromolar
ranges. From the perspective that breast milk is thought to be the
healthiest product for a newborn, this observation triggers the question
whether these plant sterols have any beneficial effects for the breast-fed
infant. Moreover, plant sterols are already present in the amniotic fluid
and the fetal circulation [50,51]. This further raises the question
whether plant sterols are beneficial for development in utero and
whether supplementation of plant sterol to the maternal diet has po-
sitive consequences for the developing fetus. Of course, one could also
argue that plant sterols and stanols might have disadvantages for de-
velopment and health, which is the reason why nature keeps levels as
low as possible.
The hypothesis that plant sterols are important perinatal, is even
more intriguing when the plant sterol composition in breast milk is
considered (Fig. 3). Apparently, plant sterol composition in breast milk
does not simply reflect circulating plant sterol concentrations in the
mother. In plasma as well as in cell membranes, campesterol con-
centrations are generally higher as compared to those of sitosterol. A
systemic review showed that human serum concentrations of sitosterol
were on average 6.92 μmol/l (95% CI 6.23/7.61 μmol/l) and those of
campesterol 13.07 μmol/l (95% CI 11.65/14.48 μmol/l) [52] However,
we observed the opposite pattern in human breast milk showing higher
sitosterol than campesterol concentrations (Fig. 3). This finding sug-
gests that the presence of plant sterols in milk is not simply extrusion of
fat globules as described for cholesterol [47]. It suggests more active
regulation of plant sterol uptake into the mammary gland and con-
sequent secretion into the milk. Indeed, ABCG5 and ABCG8 mRNA
expression was identified in bovine mammary glands [53]. Since the
sterol transporter ABCG5/G8 has a higher affinity for sitosterol
[8,54,55] than for campesterol, this could lead to a higher flux of si-
tosterol into breast milk. Moreover, this observation seems more or less
specific for humans, since milk obtained from several animals like cow,
camel and goat, except the horse, have different plant sterol composi-
tions (Table 1). Moreover, all these animals are, in contrast to humans,
pure herbivores. Considering the plant sterol and cholesterol con-
centrations in the milk from different mammals, dietary availability of
plant sterols does apparently not have a large impact on breast milk
sterol composition. Therefore, it would be intriguing to examine the
specific benefits for the neonate of the presence of plant sterols in
human breast milk. Moreover, differences in plant sterol concentrations
between milk samples of various animals is of interest and more par-
ticularly the question why the campesterol/sitosterol ratio differs be-
tween humans and herbivores. Obviously, the most prominent question
is whether these plant sterols have a role for the growing and devel-
oping newborn. A next question is whether these effects are dose- or
ratio dependent and how easily plant sterol concentrations in breast
milk can be regulated through changing maternal plant sterol intake
before and/or during the lactating period and what the optimal ma-
ternal dietary plant sterol composition is. For cholesterol, it is known
that concentrations in breast milk vary during the course of lactation
with highest levels in colostrum [56,57]. For plant sterols, it has been
suggested that their content is influenced by the composition of the
maternal diet. For infant formulas, the sterol content depends on the
types and quantity of the oils used for manufacturing. As shown in
Table 1, sitosterol levels in infant formulas are higher than those of
campesterol [58,59], due to the compositions of the vegetable oils used.
It has been estimated that formula-feeding results in plant sterol intakes
between 19 and 50mg/d [49]. While many studies have focused on the
role of fatty acids on short and long-term health of the child, no such
studies exist for plant sterols. Thus, opportunities may exist to improve
the sterol composition of maternal diets or infant formulas [60].
4. Plant sterols and immune ‘fitness’
An immune response is the resultant of two interacting and closely
collaborating parts, the innate and the adaptive immune systems. It is
evident that a resilient immune system is needed to cope with and re-
cover from the numerous challenges it is daily confronted with. An
essential challenge is the ability to distinguish between innocent and
harmful triggers, and to respond adequately to eliminating bacteria or
viruses, while tolerating for example our own cells and foods.
Moreover, a weak or hypo-responsive immune response will increase
the risk of not adequately responding to infections, whereas a hyper-
responsive immune system is thought to induce chronic inflammatory
conditions, auto-immune diseases and allergies. There are specific
conditions in which the resilience of our immune system is diminished,
for example during aging, a phenomenon called immune-senescence.
Consequently, elderly with an impaired immune response are more
susceptible to infections and have increased morbidity and mortality
rates from infections. On the other side of the lifecycle, newborns are
characterized by various parts of the immune system that are naive
such as T-cell differentiation and the number of antigen-presenting
cells, resulting in a higher risk for infections than adults has. It is a
challenge to evaluate what changes in diet and lifestyle characteristics
can be used to modulate the resilience and fitness of our immune re-
sponses.
Evidence is accumulating that several intracellular metabolic
pathways, including glycolysis, the Krebs cycle, fatty acid oxidation and
synthesis, and cholesterol synthesis tightly regulate immune cell func-
tion [61]. Several intermediate metabolites of the cholesterol synthesis
pathway may have both pro- and anti-inflammatory regulatory func-
tions. Recently, it has been reported that monocytes and macrophages
can build a long-term pro-inflammatory phenotype after short stimu-
lation, e.g. with β-glucan or with oxidized LDL particles, which has
been termed trained immunity [62]. Trained macrophages with a pro-
inflammatory phenotype display a profound upregulation of the cho-
lesterol synthesis pathway [63]. Pharmacological studies revealed that
accumulation of mevalonate is crucial for developing the trained phe-
notype, which corresponds to the increased cytokine production capa-
city of monocytes from patients with the Hyper IgD syndrome, who
have mevalonate accumulation due to a deficiency of mevalonate ki-
nase [64]. Prolonged exposure of macrophages to high cholesterol le-
vels induces characteristics of foam cell formation [65]. Interestingly,
peritoneal foam cells from LDLr−/− mice have a suppressed choles-
terol biosynthesis and an LXR-mediated downregulation of in-
flammatory pathways, which appeared to be dependent on regulated
accumulation of desmosterol [65]. Relating these observations to the
Fig. 3. Plant sterol and total cholesterol concentrations in 311 human breast
milk samples (unpublished data).
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sterol composition of breast milk, it is interesting to realize breast milk
is rich in desmosterol. Camel milk is also rich in desmosterol, while
cow, goat and horse milk are relatively desmosterol-poor. Besides these
effects of cholesterol synthesis intermediates on immune cell behavior,
there is emerging evidence that also plant sterols and stanols influence
our immune system [66]. It remains unclear whether these effects are
direct or indirect, since it is well-known that consuming plant sterols or
stanols increases endogenous cholesterol synthesis as a response to the
inhibition of intestinal cholesterol absorption [67] Therefore, it is also
possible that increased concentrations of metabolites from the choles-
terol-synthesis cascade play an important role in the observed effects of
plant sterols and stanols. Up to now, most data on the effects of plant
sterols and stanols on immune cell function originates from in vitro
experiments, whereas data from in vivo studies in animal models and/
or humans is scarce, but growing steadily.
During the last decades, an increasing number of in vitro studies
have supported immune modulation by plant sterols and stanols on
both the innate and the acquired immune system. Several studies have
examined the effects of plant sterols on the secretion of pro-in-
flammatory mediators by macrophages. In the mouse RAW264.7 mac-
rophage cell line, sitosterol reduced LPS-induced secretion of IL-6, as
well as of TNF-α [68,69]. In agreement, sitosterol suppressed IL-6, TNF-
α and INF-γ secretion via a phosphatase SHP-1-mediated inhibition of
Stat1-NFκB signaling in LPS-stimulated J774a.1 mouse macrophage-
like cells [70], and reduced activation of TLR4 receptors via MyD88 in
murine macrophages [71,72]. In addition, sitosterol stimulated anti-
oxidant responses and counteracted inflammation-induced pros-
taglandin synthesis in mouse macrophages [73–76]. Yet, Alappat et al.
[77] showed that sitosterol significantly increased IL-6, TNF-α, MCP-1,
and INF-γ. Effects on the anti-inflammatory cytokine IL-10 in LPS sti-
mulated J774a.1 cells were not consistent, since both increases as well
as decreases have been reported [70,71,78]. Another study suggested a
moderate induction of IL-6 and TNF-α secretion by sitosterol and
campesterol, but only at supra-physiological concentrations [79]. Thus,
the majority of in vitro studies support a suppressive effect of plant
sterols on LPS-induced inflammatory NFκB signaling. So far, the plant
sterol-induced modulation of the innate immune response has been
studied into detail in an endotoxin context, i.e. using LPS, whereas the
modulatory effects of plant sterols on endogenous inflammatory stimuli
such as IFN-γ, IL-β, or TNF-α remain to be elucidated.
With respect to the adaptive immune system, plant sterols and their
derivatives are suggested to skew the acquired immune response to-
wards a Th1 response, in particular in relation to Th2-driven diseases.
In vitro, a mixture of sitosterol and its glycoside (100:1) boosted T-cell
proliferation and enhanced the secretion of IL-2 and IFN-γ, but in-
hibited the secretion of IL-4 in human CD4+ T cells [68,80,81]. Other
studies showed that sitosterol, but not stigmasterol blocked the secre-
tion of Th2 cytokines (IL-4 and IL-10) [82,83]. Moreover, in human
peripheral mononuclear blood cells (PBMCs), sitosterol and sitostanol
induced a TLR2-dependent Th1 shift, featured by higher IFN-γ
production without changing the production of IL-4, IL-10 and IL-13
[84,85]. Sitosterol and sitostanol did not induce antigen presenting cell
(APC)-related IL-12 and IL-18 production in PBMCs or monocyte-de-
rived U937 cells, thereby suggesting that plant sterols and stanols do
not modulate APC-induced CD4+ T cell differentiation. Instead, they
rather push the Th-1/Th-2 balance towards a Th-1 response by enfor-
cing the production of Th-1 cytokines, which might be beneficial in
conditions characterized by decreased Th-1 responses (e.g. HIV) or in-
creased Th-2 activity (e.g. allergy) [84,86]. Regulatory T cells (Tregs)
play a crucial role in maintaining the Th1/Th2 balance by inhibiting the
activation of the dominant effector T-cells [87]. In PBMCs from Th-2
skewed asthma patients, sitostanol increased the number of Foxp3+
Tregs while stimulating IL-10 production [85]. Moreover, sitosterol
boosted stromal Tgf-β secretion, a key driver in Treg differentiation
[88]. Although speculative, it is tentative to suggest that plant sterols/
stanols enforce their Th1 skewing at least partially via Treg activation.
Although there are clear indications, more research is needed to explore
the in vitro immune-modulatory actions of plant sterols and stanols
which apparently depend on (i) the concentration and timing, (ii) the
mode of administration (e.g. vehicle or complex), (iii) the inflammatory
status of the target cells, and (iv) the relative content of the individual
plant sterols/stanols in the mixtures.
The modulatory role of plant sterols and stanols on the complex
interaction between the innate and adaptive immune response has been
evaluated in various animal models as well as in humans. Several stu-
dies have described a modulatory role for plant sterols on inflamma-
tion, in particular related to atherosclerosis and hyperlipidemia. A 2%
plant sterol-enriched diet increased IL-2 and IFN-γ production in sple-
nocytes of ApoE−/− mice after induction of acute aseptic turpentine-
induced inflammation. Splenocytes of plant sterol-fed normo-lipidemic
wild type mice injected with turpentine showed a significant elevation
in IL-2 production, but not in IFN-γ, IL-4, or IL-10 production.
Moreover, the Th1/Th2 ratio was significantly increased suggesting
that plant sterols modulated the T-helper immune response in vivo
towards a Th1 response [89]. In line, Nashed et al. showed that plant
sterol intake enhanced the capacity to mount a Th1 immune response to
a Th2-electing inflammatory stimulus in spleen cells of the hyperlipi-
demic ApoE−/− mice, featured by an increased production of IFN-γ
[90]. Also, a strong increase in the production of the Treg cytokine IL-
10 was noted. Elevated serum IL-10 levels are associated with a lower
risk of cardiovascular atherosclerotic disease (CAD) in humans [91].
Transplantation of T-cells from IL-10 overexpressing mice into LDLr−/
− mice resulted in a severe reduction in atherosclerotic lesion size
[92]. In contrast, increased levels of IFN-γ stimulated arterial in-
flammation and atherogenesis [93]. Although the plant sterol-induced
IFN-γ and IL-10 production was blocked by anti-CD4 antibodies, sup-
porting a T cell-dependent effect, a role for antigen-presenting cells
cannot be excluded. Interestingly, severe hypercholesterolemia is as-
sociated with Th1-type cytokines [94]. The immune-modulatory role of
plant sterols in mouse models of severe hyperlipidaemia may be
Table 1
Concentrations of campesterol and sitosterol and their ratio, and desmosterol and cholesterol concentrations in (breast) milk of humans and different species, or of
infant formula feedings.
Campesterol Sitosterol Ratio Desmosterol Cholesterol
(umol/L) (umol/L) Camp/Sit (umol/L) (mmol/L)
Human 0.37 ± 0.29 0.90 ± 0.58 0.50 ± 0.36 55.7 ± 25.79 0.35 ± 0.11
Camel 2.17 ± 0.66 1.75 ± 0.46 1.18 ± 0.10 27.34 ± 5.42 0.35 ± 0.06
Cow 0.75 ± 0.21 0.19 ± 0.08 4.00 ± 1.17 0.38 ± 0.32 0.24 ± 0.06
Goat 0.99 ± 0.64 0.30 ± 0.18 4.04 ± 2.36 1.09 ± 0.58 0.31 ± 0.13
Horse 0.05 ± 0.07 0.25 ± 0.20 0.23 ± 0.16 1.44 ± 0.67 0.09 ± 0.03
Formula 10.8–34.5 36.0–73.2 5.5–11.5 0.04–0.13
Unpublished data; N=311 for human milk samples and N=5 for each animal species, (means ± SD). Values for formula are given in ranges and derived from ref.
Hamdan et al. [58].
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independent of its cholesterol lowering-effect and might be mediated by
counteracting the Th2 inflammatory responses [90,94,95]. However,
the role of plant sterols on in vivo immune cell behaviour as related to
their accepted anti-atherosclerotic effects remains further study.
During the last decade, an increasing number of studies have de-
monstrated the accumulation of dietary plant sterols in the central
nervous system (CNS) [96–101]. Although ABCG5- and ABCG8-knock
out mice have higher levels of sitosterol in the circulation, levels of
campesterol are higher in brain. This suggests a controlled transport
across the blood-brain barrier. However, to the best of our knowledge,
the ABCG5/8 transporter is not detectable in the brain [97]. Recent
animal studies have investigated how plant sterols modulate neuroin-
flammatory disorders such as multiple sclerosis (MS). Experimental
autoimmune encephalitis (EAE), an animal model for MS, is a Th1/
Th17-driven immune disorders of the CNS [98]. Despite the Th1-sup-
porting trend induced by plant sterols, plant sterols counteracted the
evoked Th1 response in EAE. In particular, plant sterols beneficially
changed the course of the clinical disease, the degree of demyelination,
and the degree of immune cell infiltration into the CNS during EAE
[78]. Moreover, brain tissue homogenates and splenocyte cultures of
the EAE animals showed a reduced TNF-α release in the plant sterol-
treated mice. A potential explanation for these findings might be a plant
sterol-induced Treg-regulated restoration of the Th1/Th2 ratio. This
hypothesis is supported by the increased secretion of IL-10. Alter-
natively, a CNS parenchymal-dependent decrease in CCL2 secretion
might hamper T cell migration towards the CNS [78].
Taken together, most animal models investigating the immune-
modulatory role of plant sterols on inflammatory diseases clearly sup-
port an anti-inflammatory or immune suppressive response. Although a
plant sterol-induced strengthening of the Th1 response (Th1 skewing) is
the most prominent response under inflammatory conditions, the
nature of this Th1 skewing remains unclear. Both the modulation of the
innate immune system and a suppressive control by the regulatory T
cells appear to be involved in restoring the Th1/Th2 balance.
Nevertheless, how plant sterols or stanols modulate an inflammatory
response appears largely context and disease-dependent.
In humans, Brull et al. showed that consumption of a plant stanol
ester enriched yogurt for several weeks by allergic asthma patients
translated into rebalancing of the skewed Th2 dominant immune re-
sponse towards a more Th1 oriented immune response [102]. In this
response, enhancing the numbers and activation of regulatory T-cells
seemed to play an essential role [85]. An additional observation was the
strengthening of the Th1 response towards vaccination against
Hepatitis A, translating into higher antibody titers and reduced total IgE
concentrations. Changes in circulating plant stanol concentrations
correlated positively with the Th1/Th2 cytokine index and the change
in antibody titers suggesting a causal relationship. Interestingly, the
immune stimulating effects were particularly evident in overweight and
obese individuals, who suffered from a poor Th1-mediated immune
response at baseline (Fig. 4). (See Fig. 5.)
If plant sterol and stanol intake indeed induces Th1 skewing, a
potential risk for healthy subjects, may be that the immune system gets
out of balance, thereby inducing the risk of developing Th1-associated
conditions such as immune diseases. Theoretically, this could be a real
concern related to the garding long-term safety of increased plant
sterol/stanol intake. However, there is currently no evidence for this
suggestion, although it has however not been examined into detail.
Recently, DeSmet et al. reported in immunologically healthy human
volunteers a decrease in T-cell activity (mRNA and Treg immune
staining) in intestinal biopsies after consuming plant stanol ester en-
riched diets for 3 weeks [103]. This finding may be difficult to interpret,
since functional effects were not studied. However, these results do
indicate that in healthy individuals the (intestinal) immune system is
not Th1 over-activated after plant stanol ester consumption. Hence,
immune modulating effects may only be evident when a dis-balance
exists. As studies with healthy and hypercholesterolemic individuals did
not show changes in circulating plasma inflammation markers and cy-
tokines strengthens this suggestion [104]. Clearly, more data from
controlled intervention studies in different population groups is war-
ranted.
5. Plant sterols and CVD risk
There is no doubt that consumption of plant sterols or stanols lowers
serum LDL-cholesterol concentrations. As LDL-cholesterol is a risk
factor for CVD, lowering LDL-cholesterol by plant sterols and stanols is
expected to lower CVD [30]. A limited number of observations however
suggests that some individuals do not or poorly respond to the intake of
plant sterol or stanol enriched diets [105–107]. In addition, a higher
plant sterol intake increases circulating plant sterols concentrations.
There is an ongoing debate whether plant sterols are atherogenic or not.
Increases in absolute serum plant sterol concentrations after con-
sumption of on average 1.6 g plant sterols per day are about 31% for
sitosterol and 37% for campesterol. When standardized for plasma
cholesterol concentrations, these values are respectively 42% and 61%.
In absolute numbers, sitosterol and campesterol concentrations are
Fig. 4. Changes in antibody titers against Hepatitis A following vaccination after consuming plant sterol enriched vs placebo yogurts in normal weight (left panel)
and overweight/obese subjects (right panel) with allergic asthma (unpublished data).
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increased on average by 2.2–5.0 μmol/L as compared to an average
reduction in LDL- cholesterol of −0.33mmol/L [52]. It should be
emphasized that these plant sterol concentrations are still below those
of symptom-free heterozygous sitosterolemia patients [108]. Further-
more, consuming plant stanol esters lowers serum plant sterol con-
centrations, while serum plant stanol concentrations are increased.
However, even after increased plant stanol ester intake, serum plant
stanol concentrations are always much lower than those of serum plant
sterols (Fig. 6). Finally, plasma plant sterol levels can be used as sur-
rogate markers of fractional intestinal cholesterol absorption, but only
under steady-state conditions and when no plant-sterol enriched foods
are consumed [109–112].
The current understanding is not that elevated plasma plant sterol
concentrations per se increase the risk for CVD, but that individuals
characterized by high plant sterol concentrations can actually be clas-
sified as subjects with higher cholesterol absorption, which might in-
crease their risk for CVD [113] or stroke [114]. Based on observational
findings, the result of the discussion around the ‘plant sterol-ather-
ogenicity’ hypothesis is the following; CVD risk and its severity are
associated with higher cholesterol absorption and reciprocally with
lower cholesterol synthesis rates as measured by high levels of surro-
gate markers for cholesterol absorption (plasma/serum sitosterol,
campesterol or cholestanol) and low levels of surrogate markers for
synthesis (lathosterol or desmosterol) [113,115–122]. Interestingly, the
latest insights suggest that it seems especially the low cholesterol
synthesis that is actually driving the elevated CVD risk, an intriguing
hypothesis that has not been proven yet. Possibly, certain cholesterol
precursors such as desmosterol and mevalonate, which are low in
cholesterol-absorbers, are important for maintaining health. For ex-
ample, as discussed in the previous section, desmosterol was identified
as a strong regulator of anti-inflammation in macrophages [65] and
mevalonate as a strong inducer of trained immunity in monocytes [64].
Interestingly, cholesterol-lowering effects of plant sterols on lowering
LDL-cholesterol were most pronounced in the so-called cholesterol ab-
sorbers, who have a low endogenous cholesterol synthesis [105]. As
consumption of both plant sterol and stanol esters modestly elevates
endogenous cholesterol synthesis [67], their cardio-protective effects
may be even further increased by elevation of cholesterol synthesis
markers like desmosterol. Unfortunately, there is as yet no human trial
with clinical endpoints that has evaluated the health effects of plant
sterols or stanols. This question can only be addressed by using results
on lesion size development from animal studies with different geneti-
cally modified mouse models [123–125]. These effects maybe even
larger than can simply be explained by reductions in serum cholesterol
concentrations. For example, in female heterozygous LDLr−/− mice
fed high fat high cholesterol Western type diet, adding plant sterols,
plant stanols or atorvastatin lowered serum cholesterol concentrations
to the same extent, i.e. by 26%, 20% and 22% respectively. Thus,
cholesterol exposure was more or less reduced to the same extend in
these three groups. However, lesion sizes were reduced by 93% and
92% in the plant sterol and stanol groups, but only by 55% in the
atorvastatin group [123]. Further, Weingärtner et al. showed that
ezetimibe reduced plaque area development even more than plant
sterols did, although decreases in LDL-cholesterol were comparable
[125]. Possibly, ezetimibe reduced intestinal cholesterol absorption
even more, which might then have further enhanced compensatory
endogenous cholesterol synthesis. On the other hand, ezetimibe not
only lowers cholesterol but also circulating plant sterol concentrations.
However, if plant sterols have direct effects on lesion size formation,
Fig. 5. Potential effects of plant sterols and stanols on different cells and cell-cell interactions of the immune system.
Circulating concentrations of: 
Cholesterol:                5.5 mmol/L 
Plant sterols:  7      - 24    µmol/L (0.3    - 1.0     mg/dL)
Plant stanols: 0.05 - 0.3 µmol/L (0.002 - 0.012 mg/dL) 
500 x lower
100.000 x lower
200x lower
cholesterol
Plant
sterols Plant
stanols
Fig. 6. Average plasma cholesterol, plant sterol and stanol concentrations in the
general population.
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this would argue against this hypothesis. These considerations also raise
the question whether effects of ezetimibe mono-treatment (which
lowers intestinal cholesterol uptake and consequently increases en-
dogenous cholesterol synthesis) on CVD morbidity and mortality are
different than predicted based on reductions in LDL-cholesterol. Un-
fortunately, there are no mortality data available from a CVD endpoint
trial with ezetimibe monotherapy to address this question. The picture
becomes even more complicated when possible effects of plant sterols
on the TICE pathway are considered. TICE is an alternative excretion
route for cholesterol and activation of TICE may be atheroprotective. It
has been shown that absence of ABCG5/G8 strongly inhibits the TICE
pathway [126]. Therefore, one could be hypothesized that elevated
plant sterols are not directly involved in the pathophysiology of CVD,
but are a marker for inhibited activity in the TICE pathway.
6. Plant sterols/stanols and hepatic or intestinal diseases
Lysosomal cholesterol storage is a problem in a number of diseases
such as Niemann Pick C (NPC) deficiency, non-alcoholic steatohepatitis
(NASH), and lysosomal acid lipase deficiency (LAL)-D. In all these
conditions, the liver is affected. This indicates that appropriate cho-
lesterol fluxes and hepatic compartmentalization are essential for
normal hepatic cell function. For NASH, a high-fat diet low in dietary
cholesterol reduces the development of NASH in LDLr−/−mice [127].
It has been suggested that the flux of cholesterol from the intestine to
the liver fuels the hepatic lysosomal cholesterol accumulation thereby
triggering hepatic inflammation. This hypothesis was tested in another
study using the same NASH model, but animals were now fed a high-fat
high-cholesterol diets (HFHCD) enriched with plant sterols or stanols. It
was hypothesized that the reduced intestinal cholesterol absorption
reduced cholesterol fluxes from the intestine to the liver. Indeed, it was
shown that the diets enriched in plant sterols or stanols lowered liver
inflammation [128]. Moreover, the effect was probably specific for the
inflammatory response, since steatosis was not affected. This raises the
question whether these hepato-protective effects of plant sterols or
stanols enriched diets on liver inflammation are direct effects or in-
direct effects due to the reduced cholesterol flux. This would suggest
another indirect effect, except for the potential increased amount of
regulatory effects of the cholesterol precursors as discussed above. Of
interest, in a recent meta-analysis of human intervention studies, eze-
timibe treatment did not show consistent effects on NASH pathology
[129]. However, ezetimibe not only lowers cholesterol absorption, but
also inhibits plant sterol absorption, which results in significantly re-
duced circulating plant sterol concentrations [23,130]. This triggers the
Fig. 7. Microarray analysis in livers of LDL-receptor deficient mice fed a high-fat, high-cholesterol (HFHCD) diet (control) plus plant sterols or stanols. Panel A is the
heatmap for gene expression, panel B the correlation plot in gene expression between the HFHCD+plant sterol and HFHCD+plant stanol conditions. Panel C are
the results from ingenuity pathway analysis (IPA) for upregulated pathways in the HFHCD+plant sterol and HFHCD+plant stanol condition versus the HFHCD
condition and panel D the data from IPA for downregulated pathways in the HFHCD+plant sterol or plant stanol vs HFHCD condition (unpublished data by Plat
et al).
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question whether these observations suggests that circulating plant
sterols may have direct effects on hepatic inflammation, independent
from lowering cholesterol fluxes to the liver and of increasing cellular
cholesterol precursor concentrations. In line, both sitosterol and sitos-
tanol lowered inflammation in bone marrow derived macrophages in
vitro, i.e. independent of cholesterol fluxes [128]. However, what needs
to be considered is that plant stanols normally circulate in roughly 10-
fold lower concentrations than plant sterols, and should therefore be
much more potent than plant sterols on a molar basis.
To address the effects of plant sterols and stanol on liver in-
flammation further, their effects as part of a HFHCD on hepatic gene
expression of LDLr−/− mice were examined. The heatmap of the
microarray analyses clearly showed a reduction of inflammatory
pathways in the livers of the plant sterol and stanol fed animals (Fig. 7;
unpublished data), supporting earlier findings [128]. In agreement, the
number of resident immune cells in the livers of the plant sterol and
stanol supplemented animals was strongly reduced. The question then
arises why the migration of immune cells to the liver was decreased.
Unfortunately, this question could not be addressed, since we only had
liver material from the end of the study. At that time point there were
already significantly less immune cells and inflammation in the sterol
and stanol groups, which made it impossible to detangle cause and
consequence. However, in an acute human intervention study in which
plant stanol esters were provided to healthy human volunteers [103],
we observed a clear reduction in the intestinal expression of genes in-
volved in T-cell migration, and chemotaxis. This finding further in-
dicates that migration of immune cells is most is affected by consuming
plant sterols and stanols.
There are not many other studies that specifically evaluated the
effects of plant sterol and stanols on NASH-related outcomes. However,
in one study CardioAid™, a plant sterol extract, was administered for
25 weeks to a hyperlipidemic mouse model for NASH. Treatment with
CardioAid™ was associated with an anti-inflammatory profile resulting
in a significant decrease in the CD4/CD8 ratio and an increase in
CD4+CD25+ Treg cell numbers in plasma. Moreover, a decrease in
serum IL-1α and TGFβ levels was noted [131]. In line, a study sup-
plementing plant sterols to a rat hyperlipidemic model for NASH de-
monstrated a reduction in hepatic inflammatory cytokines TGF-β, IL-6,
IL-10, and CRP [132]. Together, the limited number of animal studies
in NASH models, support a plant sterol-mediated suppression of hepatic
inflammation.
Inflammatory bowel disease (IBD) is a group of inflammatory dis-
orders of the small intestine and colon, characterized by dysfunctional
mucosal T cells [133]. Chronic T cell resistance against apoptosis
contributes to an inappropriate T cell accumulation and the perpetua-
tion of chronic mucosal inflammation. Several studies have shown an
anti-inflammatory role of plant sterols on different aspects of IBD
[134–137]. In a T cell transfer mouse model for chronic IBD, a bene-
ficial effect of plant sterols was attributed to an increase in Foxp3+
Tregs in the colon, but only when the animal consumed a low-fat diet
[136]. In agreement, another plant derived steroid, guggulsterone, was
protective against inflammation in a Th2-mediated IBD mouse model
by attenuating neutrophil infiltration and reducing the expression of
the pro-inflammatory genes IL-2, IL-4, IL-6 and TNF-α in the colon
[135,138]. In an acute dextran sodium sulfate-induced model for IBD,
plant sterols attenuated colonic inflammation by decreasing infiltration
of inflammatory leukocytes and accelerating mucosal healing [134].
These findings, however, could not be confirmed in the study of Te
Velde et al. [136]. Except for effects on T cells, plant sterols decreased
the interaction between LPS and toll-like receptor 4 (TLR4) in intestinal
macrophages, which may have contributed to the reduced inflamma-
tion [72]. Kim et al. have investigated the effect of sitosterol on the
innate immune response in an HFD-induced colitis model in mice. Oral
sitosterol administration reduced the HFD-induced colonic inflamma-
tion and the corresponding activation of nuclear factor kappa B (NF-κB)
[72]. Sitosterol treatment in a murine 2,4,6-trinitrovenzene acid
(TNBS)-induced colitis model inhibited the production of proin-
flammatory cytokines (IL-1β, TNF-α, and IL-6) and inflammatory en-
zymes (iNos and Cox2) in the colon, indicative of NF-κB activation
[139]. Comparable results as well as NF-κB activation were found in
plant sterol-treated LPS-stimulated intestinal macrophages [72]. To
conclude, different mouse models for IBD point towards an immune-
suppressive effect by modulating both innate and adaptive immune
responses.
Uncontrolled immune activation of the gut can also occur around
birth. An infection of the amniotic fluid may provoke inflammation of
Fig. 8. Prophylactic plant sterol administration pre-
vented influx and neutrophil migration, and mucosal
damage in the ileum of preterm lambs that were
intra-amniotically exposed to LPS. Panel A: MPO-
positive cells visualized by AEC (red) in the ileum of
saline-exposed control animals. Panel B: Intra-am-
niotic LPS exposure for 7 days resulted in increased
numbers of MPO-positive cells, injured villus tips
(arrow heads) and accumulation of luminal debris.
Panel C: MPO-positive cell numbers and villus in-
tegrity were normalized by prophylactic plant sterol
treatment. (For interpretation of the references to
colour in this figure legend, the reader is referred to
the web version of this article.)
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the foetal gut, which is associated with a higher risk of adverse in-
testinal outcomes including necrotizing enterocolitis (NEC) [140,141].
NEC is an inflammatory bowel disease of neonates and one of the most
common gastrointestinal emergencies in newborn infants with high
morbidity and mortality rates [142]. Although the exact etiology and
pathophysiology of NEC is largely unknown, it is well accepted that
NEC is a complex, multi-factorial disease with currently no available
cure. Risk markers associated with NEC include prematurity, lack of
breast-feeding, and chorioamnionitis [142,143]. Considering that the
disease might have at least in part an antenatal origin, we recently
studied the effects of enrichment of the amniotic fluid with plant sterols
in a pre-clinical chorioamnionitis sheep model. In that study we showed
that foetal gut inflammation and mucosal damage following intra-am-
niotic LPS exposure was prevented by prophylactic plant sterol sup-
plementation of the amniotic fluid (unpublished data; Fig. 8). These
findings indicate that enrichment of the amniotic fluid with plant
sterols may potentially be used to prevent adverse outcomes of the
foetal gut in conditions of antenatal inflammatory stress.
7. Plant sterols in Intestinal Failure Associated Liver Disease
Parenteral nutrition (PN) is a complete macronutrient mixture that
is often combined with an intravenous lipid emulsions to supply fatty
acids and energy to support growth and development in infants and
children that cannot tolerate enteral feeding. In premature, low birth
weight infants, and infants with congenital gastrointestinal disorders,
PN support is an essential, life-saving component of clinical care.
Typically, during short-term PN treatments, complications are limited.
However, infants given longer-term PN support, particularly when
combined with a soy-based lipid emulsions (SOLE), increase the risk for
cholestasis, which is diagnosed by elevated serum total and conjugated
bilirubin, and bile acid concentrations. This type of hepatobiliary injury
is clinically identified as intestinal failure associated liver disease
(IFALD) [144]. Reports show that IFALD develops in about 20% of
infants after two weeks of parenteral SOLE feeding, and after three
months the incidence increases to> 80% [145]. Clayton et al. were the
first to observe that infants that developed IFALD had increased serum
plant sterols concentrations that correlated with disease severity
[146,147]. The underlying cause of IFALD is not due to the adminis-
tration of intravenous lipid emulsions per se, since replacement of SOLE
with fish oil-based lipid emulsions (FOLE) resulted in resolution of
IFALD [148,149]. Importantly, because FOLE contains negligible
amounts of plant sterols, these findings suggests that lack of plant
sterols in FOLE is primarily responsible for IFALD resolution [150,151].
Interestingly, patients with phytosterolemia do not develop cholestasis
or any other hepatic disease [151]. This raises the question why par-
ticularly intravenously administered (free) plant sterols cause choles-
tasis, whereas (esterified) dietary plant sterols that are absorbed from
the gut, incorporated into chylomicrons and transported to the liver do
not cause hepatic injury. It is tempting to speculate that free plant
sterols administered through PN are metabolized by different hepatic
compartments than chylomicron-derived plant sterols. Also, feeding
dietary plant sterols and stanols as part of a HFHC diet to LDLr−/−
mice improved liver function characterized by low hepatic cholesterol
levels and no inflammation [128]. It is possible that like plant sterols,
plant stanols are also involved in the PN-induced liver pathology, since
stanol concentrations increase substantially during PN regimens and
reach values above those seen during normal dietary intake. The
pharmacokinetics, organ disposition, and metabolism of plant sterols
when given orally and intravenously therefore warrants further study.
For cholesterol, it has already been shown that the metabolic effects are
different when incorporated in the liver into the cytoplasm or into the
lysosomes [152]. Another intriguing question is what would happen if
one would enrich the diet with plant sterols during partly PN and soy-
based lipid emulsion regimens? Would it be possible to counterbalance
the harmful effects of the parenterally-delivered plant sterols by
increasing the amount of diet-derived plant sterols? To summarize,
when plant sterols bypass the gut and its subsequent metabolism, i.e.
bypassing what nature had in mind when developing our metabolic
system with the gut as barrier, one should be aware of potential un-
wanted effects.
Molecular studies on the role of specific plant sterols have increased
our understanding on how these compounds may contribute to the
development of IFALD. The nuclear hormone receptor Farnesoid X
Receptor (FXR) is the primary regulator of hepatic bile acid homeostasis
through upregulating the bile salt export pump (BSEP), which facil-
itates clearance of bile acids from the liver to the bile canaliculi. Cell
culture studies in the hepatic carcinoma cell line HepG2 has shown that
administration of stigmasterol, but not sitosterol or campesterol, sup-
pressed the transactivation of luciferase reporter plasmids containing
response elements for FXR that are found in the BSEP promoter
[150,153]. Primary endogenous ligands for FXR are bile acids, with the
greatest binding affinity for chenodeoxycholic acid. Therefore, it is
possible that some plant sterols may directly interact with the binding
domain of FXR, as bile acids are derived from cholesterol and therefore
share a strong structural similarity to plant sterols. A direct role of
stigmasterol in the development of IFALD is supported in a mouse
model of PN, when mice were exposed to intestinal injury and devel-
oped a chemically-induced colitis [154]. This study also observed that
macrophages isolated from stigmasterol-supplemented mice released
more IL-6. Indeed, in isolated Kupffer cells, co-incubation with SOLE,
LPS, and exogenous plant sterols markedly increased IL-1β protein
compared to LPS alone [155]. This data suggests that plant sterols are
also potent mediators of the inflammatory response in macrophages
that have accumulated large amounts of lipids. However, it needs to be
studied into more detail whether this is true for all plant sterols or only
for stigmasterol.
Another possibility is that plant sterols in PN-regimens cause tissue
damage, because they are administered in a free form - instead of being
absorbed from the intestine and incorporated into chylomicrons, which
also contain diet-derived fat-soluble vitamins and antioxidants like to-
copherols and carotenoids. Plant sterols injected in their free form may
be more prone to oxidation. Plant sterols, as cholesterol, possess a
double bond in their ring structure and are therefore susceptible to
oxidation by non-enzymatic processes, such as reactions with reactive
oxygen species (ROS) [156]. The question is whether elevated oxy-
phytosterol concentrations in plasma translate to beneficial or un-
desirable health consequences. Studies in female LDLr+/− mice
showed that increased plasma oxyphytosterol concentrations are po-
tentially atherogenic [157]. Moreover, in humans, oxyphytosterols
have been found in aortic valve cusps [158] and circulating oxyphy-
tosterol concentrations increased postprandially after a plant sterol
enriched meal [159]. The intraperitoneal administration of non-oxi-
dized cholesterol or sitosterol did not increase of plasma oxysterol or
oxyphytosterol concentrations. Oxidative stress in the aorta was in-
creased in 7β-OH-sitosterol treated mice, but not in mice treated with
cholesterol, sitosterol, or 7β-OH-cholesterol. Moreover, cholesterol, si-
tosterol, 7β-OH-cholesterol, and 7β-OH-sitosterol did not affect en-
dothelial-dependent vasodilation or early atherosclerosis development
[160]. If oxysterol products are injurious in PN, addition of antioxidants
could be beneficial. Indeed, mixed oil lipid emulsions containing SOLE,
FOLE, olive oil, and medium chain triacylglycerols supplemented with
vitamin E suppressed the development of IFALD in piglet studies
[153,161] with comparable results in one human trial [162]. However,
the administration of supplemental vitamin E to SOLE has produced
mixed results. Addition of vitamin E to SOLE prevented the develop-
ment of PNALD in preterm piglets [163], but not in term piglets [164].
As preterm infants have impaired antioxidant defenses, these results
may suggest that plant sterol oxidation may play a role in IFALD de-
velopment. Clearly, the understand the role of oxyphytosterols in PN
conditions on IFALD warrants further study.
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8. Role of plant sterol oxidation in excretion
It is well acknowledged that cellular free cholesterol concentrations
are tightly regulated for which the cell has an arsenal of options, i.e.
esterification (ACAT), reduced synthesis (HMG-CoA reductase) and
uptake (LDLr), or enhanced secretion (ABCA1). For cellular plant
sterols, fewer options are available. It is even not known whether cells
can sense its intracellular or membrane (free) plant sterol concentra-
tion. Plant sterols are very poor substrates for ACAT making ester-
ification [165] for intracellular storage not likely. Cellular secretion
might be possible, although it is not well established to what extent
plant sterols are secreted via ABCA1. While ABCG5/G8 are of course
highly specific plant sterol transporters in enterocytes and hepatocytes,
these transporters are not ubiquitously expressed in other cell types. As
humans do not produce plant sterols, endogenous synthesis is not
regulated and the uptake is linked to uptake of lipoproteins, and related
to regulatory mechanisms for cholesterol uptake. Does this suggest that
a cell cannot actively regulate its plant sterol homeostasis? This is not
plausible, as it would mean that any cell without ABCG5/G8 would be
severely loaded with plant sterols. Therefore, we recently hypothesized
that a cell oxidizes plant sterols to form oxyphytosterols as a mechanism
to excrete plant sterols from tissues into the circulation [166]. A com-
parable mechanism is known for the brain, which secretes excess cho-
lesterol as 24-OH cholesterol across the blood-brain barrier into the
circulation [167,168].
9. Integration
The original paradigm that plant sterols and stanols are relatively
inert molecules that remain within the intestinal lumen, hardly enter
the circulation and are therefore without systemic or local effects, needs
revision. We now begin to understand that the plant sterols and stanols
that are taken up into the circulation may have systemic and cellular
effects, even if circulating and tissue concentrations are low. However,
it is also still possible that systemic effects are caused by signaling
molecules originating for example from cells in the small intestines
after plant sterol intake. This novel area of plant sterol and stanol re-
search is only in its infancy, simply because it has not received much
attention over the past decades. These new research areas, as depicted
in Fig. 9, will undoubtedly provide new insights on the health effects of
plant sterols and stanols in the very near future.
10. Conclusion
There is a need to better understand the health effects of plant
sterols and stanols, as evidence is accumulating that these compounds
have effects beyond the competition with intestinal cholesterol uptake,
resulting in decreased LDL-cholesterol concentrations. One area of in-
terest that needs further fundamental research are effects of plant
sterols and stanols on immune fitness, since there are at present hardly
any dietary approaches to intervene with immune functioning. Also,
potential effects on liver inflammation are of great interest. In this re-
spect, one needs to realize that the route of administration can be im-
portant based on findings from studies on PN and IFALD.
11. Goal of this review
The current success foods rich in plant sterols and stanols to im-
prove cholesterol metabolism is understandable and has many health
benefits. However, we here pose the intriguing question “What would
have happened if plant sterols and stanols had been discovered and
embraced by disciplines such as immunology, hepatology or rheuma-
tology before being positioned as cholesterol-lowering molecules?”
What would have been the main benefits and fields of application of
plant sterols and stanols today? There are ample emerging indications
that plant sterols and stanols have numerous effects beyond lowering
serum low-density lipoprotein (LDL) cholesterol concentrations. It
might well be that these currently largely unnoticed “additional effects”
are as important - if not even more important - compared with the es-
tablished cholesterol-lowering effects. Since their use as LDL-choles-
terol lowering dietary ingredients, it has become even more challenging
to identify such “additional effects”, because study participants in
which these potential effects might be identified are often excluded
from clinical trials that evaluate changes in cholesterol metabolism,
making unexpected findings less likely. Therefore, in this review we
discuss the effects of dietary plant sterols and stanols from a different
Cholesterol lowering
Reduce liver inflammation
(macrophages / Kupffer cells)
Improve immune function in asthma
(T-lymphocytes)
Reduce inflammatory bowel disease
(T-lymphocytes) and NEC
Improve Multiple sclerosis signs
(macrophages / microglial cells)
Fig. 9. Overview of the potential effects of plant sterols and stanols beyond lowering LDL-cholesterol concentrations that are currently studied.
J. Plat, et al. Progress in Lipid Research 74 (2019) 87–102
98
perspective with the aim to understand whether consuming plant
sterol- and stanol-rich diets could be beneficial to improve other dis-
turbed metabolic conditions or even health, and whether effects de-
pends on the health status of an individual at the time of plant sterol or
stanol consumption. Notably, from an evolutionary perspective, as
humans have also evolved in a plant-based sterol-rich environment, it
seems cholesterol-centric and not rational to think that only a process
like intestinal cholesterol absorption was affected by dietary plant
sterols and stanols. It is more likely that plant sterols and stanols played
a more imperative role in human physiology, since plant sterols and
stanols were important dietary constituents at ancient times. Therefore,
in this review we summarize the available evidence for potential effects
of plant sterols and stanols beyond lowering LDL-cholesterol. Only if we
fully understand the complete spectrum of (patho)physiological effects
of plant sterols and stanols, we can provide recommendations regarding
daily intakes to achieve optimal health benefits.
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